TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15764767

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 250 microg ex-valve (220 microg ex-actuator) four puffs twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC), 200 microg ex-valve (160 microg ex-actuator) four puffs twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ciclesonide (CIC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 14
Study: 12463328

Group type: EXPERIMENTAL
Intervention: In-line microaerosol filter
Number of subjects: 26

Group type: COMPARATOR
Intervention: Without in-line microaerosol filter
Number of subjects: 26
Study: 10603631

Group type: EXPERIMENTAL
Intervention: ADAp levels in pleural fluid > or = 40 IU and ADA1/ADAp ratio < or = 0.42
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ADAp levels in TB group
Number of subjects: 103

Group type: COMPARATOR
Intervention: ADAp levels in non-TB group
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ADA1/ADAp ratio in TB group
Number of subjects: 103

Group type: COMPARATOR
Intervention: ADA1/ADAp ratio in non-TB group
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Correlation of ADAp levels with monocyte macrophages
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Correlation of ADAp levels with lymphocytes
Number of subjects: 103
Study: 7731621

Group type: EXPERIMENTAL
Intervention: Group 1 (received information about their diagnostic procedure)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Group 2 (did not receive information, control group)
Number of subjects: 803
Study: 2119847

Group type: EXPERIMENTAL
Intervention: Gradual regarding of feeds over 48 h (regimen 1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Rapid regarding of feeds over 16 h (regimen 2)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Initial starvation followed by full normal feeds at 24 h (regimen 3)
Number of subjects: 74
Study: 533454

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 20
Study: 30897241

Group type: EXPERIMENTAL
Intervention: Late evening food consumption (TLEE after 21:00)
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Late evening food consumption (TLEE)
Number of subjects: 2642
Study: 29057609

Group type: EXPERIMENTAL
Intervention: Custom-made knee-high cast (BTCC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Custom-made ankle-high cast shoe
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prefabricated ankle-high forefoot-offloading shoe (FOS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mean peak pressure at ulcer site for BTCC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mean peak pressure at ulcer site for cast shoe
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mean peak pressure at ulcer site for FOS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stride count for BTCC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stride count for cast shoe
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stride count for FOS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percentage of 2-week intervals with device worn <50% for BTCC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percentage of 2-week intervals with device worn <50% for cast shoe
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percentage of 2-week intervals with device worn <50% for FOS
Number of subjects: 60
Study: 26795874

Group type: EXPERIMENTAL
Intervention: Rivastigmine (12 mg per day after uptitration from 3 mg per day over 12 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 130
Study: 24652865

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for community-dwelling older adults
Number of subjects: 241
Study: 22192672

Group type: EXPERIMENTAL
Intervention: Ramipril, Telmisartan, or both (exact dosages not specified)
Number of subjects: 9603
Study: 20943882

Group type: EXPERIMENTAL
Intervention: 3-dose PCV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-dose PCV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 23vPPS booster
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0-dose PCV
Number of subjects: 100
Study: 17033616

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Water and Saline (paired data)
Number of subjects: 29
Study: 16351367

Group type: EXPERIMENTAL
Intervention: Laboratory-manipulated success (Studies 1 and 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined highly positive events in the future (Study 3)
Number of subjects: 0
Study: 11991475

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) - 3 sessions of 3000 shockwaves/session at 0.2 mJ/mm2, weekly intervals for Group 1 (25 heels)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional conservative treatment (nonsteroidal anti‐inflammatory drugs, heel cup, orthoses and/or shoe modifications, local steroid injections, electrotherapy) for Group 2 (24 heels)
Number of subjects: 47
Study: 11254464

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage (12.5%) (n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 15
Study: 9730795

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension group (n = 17)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Non-pulmonary hypertension group (n = 9)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PH group (n = 17)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Non-PH group (n = 9)
Number of subjects: 26
Study: 7800166

Group type: EXPERIMENTAL
Intervention: SER282 (20 mg/ml)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Amitryptiline (AMI, 50 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 36
Study: 3154631

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 240 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 168650

Group type: EXPERIMENTAL
Intervention: Colestipol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination therapy (Clofibate or Colestipol, or Clofibrate and Cholestyramine)
Number of subjects: 57
Study: 30316810

Group type: EXPERIMENTAL
Intervention: Binge drinking (consumption of five or more doses of alcohol on a single occasion)
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Frequent/heavy drinking (alcohol consumption on six or more days)
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Use of marijuana
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Use of inhalant drugs
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Exposure to a drunk relative
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Practice of bullying
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Verbal aggression
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Intermediate/low school grades
Number of subjects: 6285

Group type: EXPERIMENTAL
Intervention: Physical aggression
Number of subjects: 6285
Study: 31456106

Group type: EXPERIMENTAL
Intervention: Robotic total/subtotal colectomy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional laparoscopic total/subtotal colectomy
Number of subjects: 82
Study: 28120005

Group type: EXPERIMENTAL
Intervention: Algorithm-based intervention group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study: 25736589

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (3 times weekly for 16 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control period (16 weeks before training)
Number of subjects: 21
Study: 22575238

Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations, 6 weekly doses
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations, 9 weekly doses
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations, 6 weekly doses (pivotal trial)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations
Number of subjects: 80
Study: 21715575

Group type: EXPERIMENTAL
Intervention: 7.5 μg MF59 adjuvanted vaccine
Number of subjects: 2

Group type: COMPARATOR
Intervention: 3.75 μg MF59 adjuvanted vaccine
Number of subjects: 2

Group type: COMPARATOR
Intervention: 15 μg nonadjuvanted vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccines
Number of subjects: 2
Study: 20033527

Group type: EXPERIMENTAL
Intervention: Dynamic chest radiography using a dynamic flat-panel detector (FPD) system
Number of subjects: 20
Study: 16957425

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 520
Study: 15103753

Group type: EXPERIMENTAL
Intervention: 3‐catheter ablation
Number of subjects: 239

Group type: COMPARATOR
Intervention: 5‐catheter ablation (control)
Number of subjects: 239
Study: 11691700

Group type: EXPERIMENTAL
Intervention: Enhanced consent procedure (computerized presentation with sequential bullet points and summaries)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine consent procedure
Number of subjects: 69
Study: 9103794

Group type: EXPERIMENTAL
Intervention: Disposable prophylaxis angle
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autoclavable prophylaxis angle
Number of subjects: 30
Study: 8104596

Group type: EXPERIMENTAL
Intervention: Remission induction with vincristine (VCR), prednisolone (PRED), and L-asparaginase (L-Asp)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Consolidation course with cyclophosphamide (CP) and cytarabine (AraC) for SR and IR groups; two courses for HR group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis randomized using either cranial irradiation 18 Gy + 5 intrathecal methotrexate (IT MTX) or triple IT with maintenance
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Reinforcement cycles during maintenance therapy (6-mercaptopurine+MTX)
Number of subjects: 212
Study: 3097178

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.22 mg X kg‐1, range 0.15‐0.38)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal diazepam (0.58 mg X kg‐1, range 0.50‐0.71)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous and rectal diazepam
Number of subjects: 0
Study: 30238247

Group type: EXPERIMENTAL
Intervention: N3b1 patients (16-20 metastatic lymph nodes)
Number of subjects: 222

Group type: COMPARATOR
Intervention: N3b2 patients (≥21 metastatic lymph nodes)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Palliative surgery group
Number of subjects: 222
Study: 29605135

Group type: EXPERIMENTAL
Intervention: Biodiesel exhaust exposure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study: 27896908

Group type: EXPERIMENTAL
Intervention: Bixalomer (1500 mg/day adjusted up to 7500 mg/day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Bixalomer
Number of subjects: 163
Study: 25250612

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (for patients >= 20 kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 28
Study: 22253199

Group type: EXPERIMENTAL
Intervention: Dexamethasone Sinu-Foam™ mixture (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (Sinu-Foam™ alone, n = 18)
Number of subjects: 36
Study: 20434606

Group type: EXPERIMENTAL
Intervention: Nabilone (0.5mg once a day, with option to increase to 0.5mg twice a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17512160

Group type: EXPERIMENTAL
Intervention: rhu-GMCSF, 125 microg/m2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (GMCSF and Control)
Number of subjects: 36
Study: 16283978

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique using a laryngoscope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open saphenous vein harvest
Number of subjects: 30
Study: 12514774

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg orally twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 500 mg orally twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 250 mg orally twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched oral placebo twice daily
Number of subjects: 30
Study: 10333095

Group type: EXPERIMENTAL
Intervention: TT-S (tremometer test adapted for the rifle in the standing position)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RT-P (visual reaction time test in the prone position)
Number of subjects: 24
Study: 8961069

Group type: EXPERIMENTAL
Intervention: lisinopril or captopril
Number of subjects: 30
Study: 1761082

Group type: EXPERIMENTAL
Intervention: Oral controlled release salbutamol 4 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral controlled release salbutamol 8 mg
Number of subjects: 8
Study: 7108069

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BD), 0.05 mg three times daily, sprayed in each nostril
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 39
Study: 3905468

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once at night
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31712971

Group type: EXPERIMENTAL
Intervention: SAMe 800 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 29032252

Group type: EXPERIMENTAL
Intervention: Articulating advanced bipolar device (ENSEAL G2)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Electrothermal bipolar vessel sealer (LigaSure)
Number of subjects: 140
Study: 27741342

Group type: EXPERIMENTAL
Intervention: FMX‐102 1%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FMX‐102 4%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FMX‐102 1% and 4%
Number of subjects: 32
Study: 25018015

Group type: EXPERIMENTAL
Intervention: 100 mg/day JNJ-40929837 for 6 days followed by 50 mg/day on day 7
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 mg/day montelukast for 6 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 22
Study: 22080400

Group type: EXPERIMENTAL
Intervention: home‐based pencil push‐ups
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: home‐based computer vergence/accommodative therapy and pencil push‐ups
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: office‐based vergence/accommodative therapy with home reinforcement
Number of subjects: 218

Group type: COMPARATOR
Intervention: office‐based placebo therapy with home reinforcement
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Successful outcome
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Improved outcome
Number of subjects: 218
Study: 21079217

Group type: EXPERIMENTAL
Intervention: Transdermal DHT (70 mg) daily for 2 years
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo gel daily for 2 years
Number of subjects: 114
Study: 18218905

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO; sucrose) at 0.96 g.kg(‐1).h(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA) gels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO; sucrose)
Number of subjects: 10
Study: 17081356

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow mononuclear cell (BM‐MNCs) transplantation (5.0 +/- 0.7 x 10^7)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 30
Study: 11435264

Group type: EXPERIMENTAL
Intervention: Sertraline 50-150 mg for 24 weeks
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Combined sertraline and exposure therapy
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 9926765

Group type: EXPERIMENTAL
Intervention: Combination of amoxicillin and metronidazole therapy as an adjunct to mechanical treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mechanical treatment and antibiotics
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mechanical treatment and placebo
Number of subjects: 25
Study: 8054806

Group type: EXPERIMENTAL
Intervention: Aminophylline 3 mg/kg before protamine administration
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 34
Study: 3127852

Group type: EXPERIMENTAL
Intervention: Total cigarette cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% reduction of number of cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduction of nicotine yield of cigarettes
Number of subjects: 0
Study: 29562080

Group type: EXPERIMENTAL
Intervention: 9‐session Bridges/Puentes family‐focused group intervention
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control workshop
Number of subjects: 516
Study: 27258122

Group type: EXPERIMENTAL
Intervention: BOLUS score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2h-BOLUS score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TOTAL-BOLUS score
Number of subjects: 100

Group type: COMPARATOR
Intervention: Frequency of glucose monitoring
Number of subjects: 100
Study: 25113524

Group type: EXPERIMENTAL
Intervention: Healthy Experiences After Loss (HEAL)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study: 22155702

Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19940276

Group type: EXPERIMENTAL
Intervention: Genetically reduced soluble epoxide hydrolase activity (EPHX2 genotypes)
Number of subjects: 10000
Study: 18535395

Group type: EXPERIMENTAL
Intervention: Baseline social ties and emotional support
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Social ties
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Social exposures
Number of subjects: 272
Study: 16052104

Group type: EXPERIMENTAL
Intervention: Heparinase I (maximum 35 microg/kg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Protamine (maximum 650 mg)
Number of subjects: 167
Study: 12537671

Group type: EXPERIMENTAL
Intervention: Anti-idiotypic monoclonal antibodies (Ab2) 2H4 or 5D3 with aluminum hydroxide-precipitated, accompanying radiotherapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 19
Study: 10473030

Group type: EXPERIMENTAL
Intervention: Flosequinan and its metabolite
Number of subjects: 0
Study: 7600887

Group type: EXPERIMENTAL
Intervention: Iron supplement every other two days
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Iron supplement each week
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Iron supplement every day
Number of subjects: 238
Study: 1699764

Group type: EXPERIMENTAL
Intervention: Etodolac 200 or 300 mg b.i.d. or 200 mg t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac 50 mg b.i.d. or 50 mg t.i.d.
Number of subjects: 0
Study: 324503

Group type: EXPERIMENTAL
Intervention: Flunixin (SCH 14714)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31327127

Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 117015066

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 117015066

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 117015066

Group type: EXPERIMENTAL
Intervention: Albuterol (β-agonist)
Number of subjects: 117015066

Group type: EXPERIMENTAL
Intervention: Propranolol (β-blocker)
Number of subjects: 117015066

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 117015066
Study: 30400773

Group type: EXPERIMENTAL
Intervention: Standardized questionnaire sent to GPs
Number of subjects: 1000
Study: 26967719

Group type: EXPERIMENTAL
Intervention: Elastic taping
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neoprene sleeve
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soccer cleat without external support (untaped control)
Number of subjects: 20
Study: 24447238

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3522
Study: 22265360

Group type: COMPARATOR
Intervention: Medication alone (risperidone 0.5 to 3.5 mg/day; n = 49)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Medication plus parent training (average of 11.4 PT sessions; n = 75)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Medication plus parent training (n = 75)
Number of subjects: 124
Study: 20354007

Group type: EXPERIMENTAL
Intervention: Rested condition
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sleep deprived condition
Number of subjects: 29